Tilray, Inc. Reports Fourth Quarter and Full Fiscal Year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Eight Capital Downgrades Tilray (TLRY) to Neutral
March 3, 2020 6:42 AM ESTEight Capital analyst Graeme Kreindler downgraded Tilray (NASDAQ: TLRY) from Buy to Neutral with a price target of $17.00 (from $26.00).
For an analyst ratings summary and ratings history on Tilray click here. For more ratings news on Tilray click here.
Shares of Tilray closed at $13.80 yesterday.
... MoreTilray, Inc. (TLRY) Misses Q4 EPS by 27c, Revenues Miss
March 2, 2020 4:11 PM ESTTilray, Inc. (NASDAQ: TLRY) reported Q4 EPS of ($0.62), $0.27 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $46.94 million versus the consensus estimate of $55.38 million.
Fourth Quarter 2019 Financial Highlights
Revenue increased 202.2% to $46.9 million (C$61.0 million), compared to the fourth quarter of last year, driven by the Canadian adult-use market, the Manitoba Harvest acquisition, and growth in international medical markets. The Company recorded reserves of $4.2 million related to discounts and returns.Total cannabis kilogram equivalents sold increased over seven-fold to 15,039 kilograms from... More